Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 11:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 421 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Metformin Placebo Clear all
Not listed Phase 1Phase 2 Interventional

Metformin in Patients With Fragile X

NCT04141163
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
Metformin, Placebo oral tablet
Drug
Lead sponsor
Rowan University
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Stratford, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Sep 3, 2026, 11:23 PM EDT
Enrolling by invitation Early Phase 1 Interventional

Intertrochanteric Femur Fracture Patients Who Receive Metformin With a Placebo

NCT07179042
View directory record Official record
Conditions
Intertrochanteric Femur Fracture, Muscle Atrophy
Interventions
Placebo, Metformin
Drug
Lead sponsor
University of Utah
Other
Eligibility
60 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 3, 2026, 11:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cortisol Regulation in Polycystic Ovary Syndrome (PCOS)

NCT00694759
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
pioglitazone, metformin, placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 8, 2019 · Synced Sep 3, 2026, 11:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized, Placebo-controlled Study to Evaluate Effects of E5555 on Renal Function Parameters and OCT2 Activity

NCT01241669
View directory record Official record
Conditions
Healthy Subjects
Interventions
E5555
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Sep 3, 2026, 11:23 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia

NCT05237960
View directory record Official record
Conditions
Erythroplakia, Oral Leukoplakia
Interventions
Biopsy, Biospecimen Collection, Extended Release Metformin Hydrochloride, Placebo Administration
Procedure · Drug
Lead sponsor
University of Arizona
Other
Eligibility
21 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Tucson, Arizona • San Diego, California • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 3, 2026, 11:23 PM EDT
Active, not recruiting Phase 2 Interventional

The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)

NCT04207944
View directory record Official record
Conditions
IPMN, IPMN, Pancreatic
Interventions
Sulindac 400 MG, Placebo
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
21 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 3, 2026, 11:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Metformin Effect on Brain Function in Insulin Resistant Elderly People

NCT03733132
View directory record Official record
Conditions
Insulin Resistance, Obesity, Obesity, Abdominal
Interventions
Metformin Hydrochloride, Placebo Oral Tablet
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Sep 3, 2026, 11:23 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus

NCT00760344
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
SYR-472, Placebo, Sitagliptin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
105
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 102 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Sep 3, 2026, 11:23 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes

NCT01023581
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Alogliptin, Metformin, Alogliptin Placebo, Metformin Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
109
States / cities
Dothan, Alabama • Muscle Shoals, Alabama • Pell City, Alabama + 106 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced Sep 3, 2026, 11:23 PM EDT
Completed Phase 4 Interventional

Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)

NCT04979130
View directory record Official record
Conditions
Type 2 Diabetes, Chronic Inflammation, Intestinal Permeability
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Sep 3, 2026, 11:23 PM EDT
Completed Phase 2 Interventional

CS02 vs Placebo With Metformin in Type 2 Diabetes Mellitus (T2DM)

NCT03317028
View directory record Official record
Conditions
T2DM With Inadequate Glycemic Control
Interventions
CS02 tablet and placebo tablet
Drug
Lead sponsor
Center Laboratories, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Little Rock, Arkansas • Coral Gables, Florida • Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Jun 8, 2020 · Synced Sep 3, 2026, 11:23 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin

NCT00603239
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Birmingham, Alabama • Concord, California • Fresno, California + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 3, 2026, 11:23 PM EDT
Not yet recruiting Early Phase 1 Interventional

Metformin and ACLR Muscle Recovery

NCT07699367
View directory record Official record
Conditions
Atrophy, Inflammation, Weakness, Muscle
Interventions
Metformin, Placebo
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 3, 2026, 11:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Milk Protein Feeding After Aerobic Exercise in Older Adults With Pre-diabetes Taking the Biguanide Metformin

NCT02552355
View directory record Official record
Conditions
Physical Activity
Interventions
Metformin, Placebo, Carbohydrate Beverage, Protein Beverage
Drug · Dietary Supplement
Lead sponsor
Colorado State University
Other
Eligibility
55 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Sep 3, 2026, 11:23 PM EDT
Completed Phase 2 Interventional Results available

Ursodiol on Insulin Sensitivity, Gastric Emptying and Body Weight With Type 2 Diabetes on Metformin

NCT02033876
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ursodiol
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Sep 3, 2026, 11:23 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes

NCT01606007
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Metformin XR, Dapagliflozin, Placebo matching with Dapagliflozin, Placebo matching with Saxagliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
80
States / cities
Birmingham, Alabama • Homewood, Alabama • Muscle Shoals, Alabama + 73 more
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 3, 2026, 11:23 PM EDT
Completed Phase 2 Interventional Results available

Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus

NCT01336738
View directory record Official record
Conditions
Diabetes, Type 2
Interventions
Placebo, 150 mg PF-04991532, 450 mg PF-04991532, 750 mg PF-04991532, Sitagliptin 100 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
28
States / cities
Jonesboro, Arkansas • Los Angeles, California • Palm Springs, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2013 · Synced Sep 3, 2026, 11:23 PM EDT
Terminated Phase 4 Interventional Results available

MEtformin and Lorcaserin for WeighT Loss in Schizophrenia

NCT02796144
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Overweight
Interventions
Lorcaserin, Metformin, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Augusta, Georgia • New York, New York • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Sep 3, 2026, 11:23 PM EDT
Completed Phase 2 Interventional Results available

Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02122185
View directory record Official record
Conditions
Brenner Tumor, Malignant Ascites, Malignant Pleural Effusion, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Cavity Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Primary Peritoneal Cavity Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Primary Peritoneal Cavity Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Primary Peritoneal Cavity Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Primary Peritoneal Cavity Cancer
Interventions
metformin hydrochloride, placebo, Chemotherapy
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
10
States / cities
Birmingham, Alabama • Mobile, Alabama • Duarte, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 3, 2026, 11:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Metabolic Effect of Metformin in Obese Insulin Resistant Adolescents With Normal Glucose Tolerance

NCT00667498
View directory record Official record
Conditions
Pediatric Obesity, Insulin Resistance, Hyperinsulinemia
Interventions
Metformin, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
13 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 17, 2009 · Synced Sep 3, 2026, 11:23 PM EDT
Completed Phase 2 Interventional Results available

Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With Type 2 Diabetes Mellitus (T2DM)

NCT01889667
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
ORMD-0801 Dose # 1, ORMD-0801 Dose # 2, Placebo
Drug
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
20 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Sep 3, 2026, 11:23 PM EDT
Completed Phase 3 Interventional

A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

NCT06109311
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
25
States / cities
Chandler, Arizona • Phoenix, Arizona • Bryant, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 3, 2026, 11:23 PM EDT
Completed Phase 2 Interventional

A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.

NCT00423501
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Placebo, taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Woodstock, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 3, 2026, 11:23 PM EDT
Terminated Early Phase 1 Interventional Results available

Cardiometabolic Disease and Pulmonary Hypertension

NCT03349775
View directory record Official record
Conditions
Obesity
Interventions
Metformin, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Sep 3, 2026, 11:23 PM EDT